New Stock News: Hemei Pharmaceutical has once again submitted documents to the Hong Kong Stock Exchange, with pipeline products covering seven small molecule drug candidates.

According to the Securities Times app, it was disclosed by the Hong Kong Stock Exchange on June 8 that Ganzhou Hemei Pharmaceuticals Co., Ltd.-B (referred to as Hemei Pharmaceuticals) has once again submitted an application to the Hong Kong Stock Exchange's main board, with Guotou Securities International as its exclusive sponsor.